Multimodality therapy for esophageal cancer

ONCOLOGY

Volumn 24, Issue 12, 2010, Pages

  Krasna, Mark J ^a  

^a Cancer Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; CISPLATIN; EPIRUBICIN; FLUOROURACIL; GEFITINIB;

ASPIRATION BIOPSY; CANCER INCIDENCE; CANCER STAGING; CLINICAL TRIAL; DIARRHEA; ESOPHAGEAL ADENOCARCINOMA; ESOPHAGUS CANCER; ESOPHAGUS RESECTION; GASTROESOPHAGEAL REFLUX; HUMAN; POSITRON EMISSION TOMOGRAPHY; PROGNOSIS; RASH; REVIEW; ULTRASOUND;

EID: 78649684424     PISSN: 08909091     EISSN: 08909091     Source Type: Journal    
DOI: None     Document Type: Review

References (26)

1. Duan L, Wu AH, Sullivan-Halley J, et al. Passive smoking and risk of oesophageal and gastric adenocarcinomas. Br J Cancer. 2009;100:1483-85.
2. Lu XM, Monnier-Benoit S, Mo LZ, et al. Human papillomavirus in esophageal squamous cell carcinoma of the high-risk Kazakh ethnic group in Xinjiang, China. Eur J Surg Oncol. 2008;34:765-70.
3. Lagergren J, Ye W, Lagergren P, et al. The risk of esophageal adenocarcinoma after antireflux surgery. Gastroenterology. 2010;138:1297-1301.
4. Mezhir JJ, Coit DG, Jacks LM. Impact of positive peritoneal cytology on outcome in 291 patients with gastric cancer. Abstract presented at 2010 Gastrointestinal Cancers Symposium; 2010 Jan 22-24; Orlando, Fla.
5. Liptay MJ, DAmico TA, Nwogu C, et al. Intraoperative SLN mapping in lung cancers. B J Thorac Oncol. 2010;4:198-202.
6. Grotenhuis BA, Wijnhoven BP, van Marion R, et al. The sentinel node concept in adenocarcinomas of the distal esophagus and gastroesophageal junction. J Thorac Cardiovasc Surg. 2010;138:608-12.
7. Rice TW, Rusch VW, Apperson-Hansen C, et al. Worldwide esophageal cancer collaboration. Dis Esophagus. 2009;22:1-8.
8. Rizk NP, Ishwaran H, Rice TW, et al. Optimum lymphadenectomy for esophageal cancer. Ann Surg. 2010;251:46-50.
9. Gaur P, Hofstetter W, Bekele BN, et al. Comparison between established and the worldwide esophageal cancer collaboration staging systems. Ann Thorac Surg. 2010;89:1797-1804.
10. American Joint Committee on Cancer. Edge SB, Byrd DR, Compton CC, et al, editors. Cancer staging manual. 7th ed. New York: Springer; 2010.
11. International Union Against Cancer. Staging malignant tumors. In: Sobin LH, Gospodarowicz MK, Wittekind C, editors. TNM classification of malignant tumours. 7th ed. Oxford: Wiley-Blackwell; 2009.
12. Javeri H, Xiao L, Rohren E, et al. The higher the decrease in the standardized uptake value of positron emission tomography after chemoradiation, the better the survival of patients with gastroesophageal adenocarcinoma. Cancer. 2009;115:5184-92.
13. Bolton WD, Hofstetter WL, Francis AM, et al. Impact of tumor length on long-term survival of pT1 esophageal adenocarcinoma. J Thorac Cardiovasc Surg. 2009;138:831-6.
14. Brooke BS, Meguid RA, Makary MA, et al. Improving surgical outcomes through evidence based measures. Surgery. 2010;147:481-90.
15. Skipworth RJ, Parks RW, Stephens NA, et al. The relationship between hospital volume and post-operative mortality rates for upper gastrointestinal cancer resections Scotland 1982-2003. Eur J Surg Oncol. 2010;36:141-47.
16. Boudourakis LD, Wang TS, Roman SA, et al. Evolution of the surgeon-volume, patient-outcome relationship. Ann Surg. 2009;250:159-65.
17. Parameswaran R, Veeramootoo D, Krishnadas R, et al. Comparative experience of open and minimally invasive esophagogastric resection. World J Surg. 2009;33:1868-75.
18. Yannopoulos P, Theodoridis P, Manes K. Esophagectomy without thoracotomy: 25 years of experience over 750 patients. Langenbecks Arch Surg. 2009;394:611-6.
19. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodality therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462-7. (Pubitemid 26269945)
20. Tepper J, Krasna M, Niedzwiecki D, et al. Phase III trial of trimodality therapy with cisplatin, fluorouracil, radiotherapy, and surgery compared with surgery alone for esophageal cancer: CALGB 9781. J Clin Oncol. 2008;26:1086-92.
21. Diaz R, Reynes G, Tormo A, et al. Long-term results of neoadjuvant chemotherapy and combined chemoradiotherpy before surgery in the management of locally advanced oesophageal cancer: a single-center experience. Clin Transl Oncol. 2009;11:835-41.
22. Jin HL, Zhu H, Ling TS, et al. Neoadjuvant chemoradiotherpy for resectable esophaegal carcinoma: a meta-analysis. World J Gastroenterol. 2009;15:5983-91.
23. Rodriguez CP, Adelstein DJ, Rice TW, et al. A phase II study of perioperative concurrent chemotherapy, gefitinib, and hyperfractionated radiation followed by maintenance gefitinib in locoregionally advanced esophagus and gastroesophageal junction cancer. J Thorac Oncol. 2010;5:229-35.
24. Schreiber D, Rineer J, Vongtama D, et al. Impact of postoperative radiation after esophagectomy for esophageal cancer. J Thorac Oncol. 2010;5:244-250.
25. Stahl M, Walz MK, Stuschke M, et al. Phase III comparison of preoperative chemotherapy compared with chemoradiotherapy in patients with locally advanced adenocarcinoma of the esophagogastric junction. J Clin Oncol. 2009;27:851-6.
26. Starling N, Okines A, Cunningham D. A phase II trial of preoperative chemotherapy with epirubicin, cisplatin and capecitabine for patients with localised gastro-oesophageal junctional adenocarcinoma. Br J Cancer. 2009;100:1725-30.